New treatment option for active lupus nephritis!
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Recent Posts
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Through Cardiometabolic ...
Navigating Growth in Latin American Pharmaceuticals
In the Latin American pharmaceuticals sector, Bausch Health is strategically expanding its footprint under the leadership of Vice President Fernando Zarate. The company's operati...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...
Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Aligning U.S. Childhood Immunization Schedules with International Benchmarks
Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...